TrialUnited European gastroenterology journal2019

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Anca Trifan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.